methyl 2-methyl-2-(5-cyano-2-pyridyloxy)propionate | 883858-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 2-methyl-2-(5-cyano-2-pyridyloxy)propionate
• 英文别名: methyl 2-(5-cyanopyridin-2-yl)oxy-2-methylpropanoate
• CAS: 883858-22-8
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: HETAKAHHNBUISQ-UHFFFAOYSA-N

物化性质

• 沸点：
  330.4±27.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-methyl-2-(5-cyano-2-pyridyloxy)propionate 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 2-methyl-2-(5-cyano-2-pyridyloxy)propionic acid
  参考文献：
  名称：

  [EN] RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS
  [FR] MODULATEURS RADIOMARQUES DU RECEPTEUR DE CANNABINOIDE-1

  摘要：

  本发明涉及特定的放射标记的大麻素-1（CB1）受体调节剂，以及使用这些调节剂进行哺乳动物，特别是人类大麻素-1受体的标记和诊断成像的方法。此外，还公开了用于合成放射标记的大麻素-1受体调节剂的中间体，以及用于合成放射标记的大麻素-1受体调节剂的过程。此外，还描述了放射标记的大麻素-1受体化合物的配方。

  公开号：

  WO2005009479A1
• 作为产物：
  描述：

  2-(5-氯吡啶-2-基氧基)-2-甲基丙酸 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 、 三丁基氯化锡 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 0.25h， 生成 methyl 2-methyl-2-(5-cyano-2-pyridyloxy)propionate
  参考文献：
  名称：

  Discovery of N-{(1S,2S)-2-(3-Cyanophenyl)- 3-[4-(2-[¹⁸F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a Cannabinoid-1 Receptor Positron Emission Tomography Tracer Suitable for Clinical Use

  摘要：

  The discovery of a structurally distinct cannabinoid-1 receptor (CB1R) positron emission tomography tracer is described. Starting from an acyclic amide CB1R inverse agonist (1) as the lead compound, an efficient route to introduce F-18 to the molecule was developed. Further optimization focused on reducing the lipophilicity and increasing the CB1R affinity. These efforts led to the identification of [F-18]-16 that exhibited good brain uptake and an excellent signal-to-noise ratio in rhesus monkeys.

  DOI：

  10.1021/jm070131b

文献信息

• Substituted amides
  申请人：Burns H. Donald

  公开号：US20060115425A1

  公开（公告）日：2006-06-01

  The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

  本发明涉及特定的放射性标记的Cannabinoid-1（CB1）受体调节剂，以及使用这些调节剂进行哺乳动物，特别是人类Cannabinoid-1受体的标记和诊断成像的方法。此外，还公开了用于合成放射性标记的Cannabinoid-1受体调节剂的中间体，以及合成放射性标记的Cannabinoid-1受体调节剂的过程。此外，还描述了放射性标记的Cannabinoid-1受体化合物的配方。
• Acyclic Hydrazides as Cannabinoid Receptor Modulators
  申请人：Lin S. Linus

  公开号：US20080076805A1

  公开（公告）日：2008-03-27

  The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  本发明提供的无环脒肼类化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（包括多发性硬化和格林-巴利综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。该化合物还可用于治疗物质滥用障碍（包括戒烟）、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。
• Radiolabeled cannabinoid-1 receptor modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07754188B2

  公开（公告）日：2010-07-13

  The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

  本发明涉及特定的放射标记的Cannabinoid-1（CB1）受体调节剂，以及使用这些调节剂标记和诊断成哺乳动物，特别是人类的Cannabinoid-1受体的成像方法。此外，还揭示了用于合成放射性标记的Cannabinoid-1受体调节剂的中间体，以及合成放射性标记的Cannabinoid-1受体调节剂的过程。还描述了放射性标记的Cannabinoid-1受体化合物的配方。
• [EN] ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS<br/>[FR] HYDRAZIDES ACYCLIQUES UTILES EN TANT QUE MODULATEURS DU RECEPTEUR CANNABINOIDE
  申请人：MERCK & CO INC

  公开号：WO2006041797A3

  公开（公告）日：2006-07-06
• Synthesis and biological evaluation of heterocycle containing adamantane 11β-HSD1 inhibitors
  作者：Vince S.C. Yeh、Jyoti R. Patel、Hong Yong、Ravi Kurukulasuriya、Steven Fung、Katina Monzon、William Chiou、Jiahong Wang、Deanne Stolarik、Hovis Imade、David Beno、Michael Brune、Peer Jacobson、Hing Sham、J.T. Link

  DOI：10.1016/j.bmcl.2006.07.055

  日期：2006.10

  A series of metabolically stable adarnantane amide 11 beta-HSD1 inhibitors have been synthesized and biologically evaluated. These compounds exhibit excellent HSD1 potency and HSD2 selectivity and good pharmacokinetic and pharmacodynamic profiles. (c) 2006 Elsevier Ltd. All rights reserved.